-+ 0.00%
-+ 0.00%
-+ 0.00%

Theralase Reports 64.5% Complete Response Rate in Phase II Bladder Cancer Study

PUBT·10/26/2026 11:12:21
Theralase Reports 64.5% Complete Response Rate in Phase II Bladder Cancer Study
  • Theralase Technologies reported interim Phase II results on October 26, 2026, for light-activated Ruvidar in BCG-unresponsive non-muscle-invasive bladder cancer.
  • Patients achieved complete responses, with some maintaining responses long term; interim findings supported an acceptable safety profile.
  • Clinical data are being prepared for Canadian and US regulatory submissions, with marketing decisions anticipated in 2027.
  • Global licensing agreements for marketing and distribution are planned for 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Theralase Technologies Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 202610260700NEWSFILECNPR____20261026_320824_1) on October 26, 2026, and is solely responsible for the information contained therein.